Evotec SE has signed a definitive agreement to acquire Just Biotherapeutics, Inc., based in Seattle, WA, for as much as $90 million in cash, including potential performance-based earn-out components expected within the next three years.

Just.Bio is a technology company that integrates highly synergistic scientific expertise and technologies for design, development, and manufacturing of biologics. The acquisition expands Evotec’s service offering including biologics in therapeutic areas such as oncology, CNS, pain, inflammation, metabolics, and infectious diseases. Just.Bio has approx. 90 employees, mainly scientists, all working at a state-of-the-art discovery, development and manufacturing facility in Seattle.

The transaction, subject to customary closing conditions, is expected to close in 2Q19.